4-benzyledene-piperidin derivatives
AssigneeRichter Gedeon Vegyeszeti Gyar Rt.
InventorsIstvan Borza, Csilla Horvath, Sandor Farkas, Istvan Gyertyan, Jozsef Nagy, Sandor Kolok, Kornel Galgoczy, Katalin Saghy
Life of this patent
Estimating the term…
Abstract
The present invention relates to new 4-benzylidene-piperidin derivatives of formula (I), useful as NMDA, in a particular NR2B subunit containing receptor antagonists and analgesica.
Claims8
New 4-benzylidene-piperidin derivatives of formula (I)
- wherein the neighboring X and Y groups together form an optionally substituted ring selected from pyrrolidine, oxo- or thioxo-pyrrolidine;
- imidazolidine, oxo- or thioxo-imidazolidine, oxazolidine, oxo- or thioxo-oxazolidine and oxo- or thioxo-thiazolidine;
- Z is hydrogen or halogen atom, nitro, amino, C1-C4 alkyl, C1-C4 alkoxy, cyano,trifluoromethyl, trifluoromethoxy group—and optical antipodes, racemates and salts thereof.
A method of treating a disease, in a mammal or human in need thereof, selected from traumatic injury of brain or spinal cord, human immunodeficiency virus(HIV) related neuronal injury, amyotrophic lateral sclerosis, tolerance and/or dependence to opioid treatment of pain, withdrawal syndromes of alcohol, opioids or cocaine, excitotoxicity evoked by brain hypoxia or ischemia, chronic neurodegeneration in Alzheimer's disease, Parkinson's disease or Huntington's disease, pain, chronic pain, neuropathic pain or cancer related pain, epilepsy, anxiety, depression, migraine, psychosis, muscular spasm, dementia of various origin, degenerative disorders of the retina, glaucoma, asthma, tinnitus, and aminoglycoside antibiotic-induced hearing loss comprising administering an effective amount of a compound of formula (I), or optical antipode or racemate or the pharmaceutically acceptable salt thereof, to said mammal or human.
Dependencies are inferred from the claim text.